Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT in active ulcerative colitis
NL-OMON59161Phase 4Completed
- Sponsor
- Alimentiv Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Alimentiv Inc. Primary endpoint: Time to ulcerative colitis-related complication in the achieved-target population. Started Jun 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59161.